Similar articles

• Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.

  Mordasini R, Riesen W, Oster P, Keller M, Middelhoff G, Lang PD. Mordasini R, et al. Atherosclerosis. 1981 Oct;40(2):153-8. doi: 10.1016/0021-9150(81)90033-2. Atherosclerosis. 1981. PMID: 6796096
• [Bezafibrate and delayed action etofibrate in hyperlipidemia].

  Lang PD, Vollmar J. Lang PD, et al. Dtsch Med Wochenschr. 1983 Feb 25;108(8):302-5. doi: 10.1055/s-2008-1069545. Dtsch Med Wochenschr. 1983. PMID: 6825604 German. No abstract available.
• Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.

  Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J. Stewart JM, et al. Atherosclerosis. 1982 Sep;44(3):355-65. doi: 10.1016/0021-9150(82)90010-7. Atherosclerosis. 1982. PMID: 6293516
• Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

  Fruchart JC, Duriez P. Fruchart JC, et al. Drugs Today (Barc). 2006 Jan;42(1):39-64. doi: 10.1358/dot.2006.42.1.963528. Drugs Today (Barc). 2006. PMID: 16511610 Review.
• Effect of fibric acid derivatives on blood lipid and lipoprotein levels.

  Hunninghake DB, Peters JR. Hunninghake DB, et al. Am J Med. 1987 Nov 27;83(5B):44-9. doi: 10.1016/0002-9343(87)90870-9. Am J Med. 1987. PMID: 3318453 Review.